Drug discovery and beyond: The role of public-private partnerships in improving access to new malaria medicines

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 99, Issue SUPPL. 1, 2005, Pages 20-29

  Nwaka, Solomon ^a,b  

^a Medicines for Malaria Venture   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antimalarial drugs; Disease endemic countries; Drug access; Medicines for Malaria Venture; Public private partnership for product development; Translational research

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEKIN; ARTEMETHER PLUS BENFLUMETOL; ARTEMIFONE; ARTEMISININ DERIVATIVE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CYSTEINE PROTEINASE INHIBITOR; DB 289; DB 829; DIHYDROARTEMISININ; DIHYDROFOLATE REDUCTASE INHIBITOR; FANSIDAR; GW 844520; HALOFANTRINE; IMIDAZOLIDINE DERIVATIVE; MEFLOQUINE; NATURAL PRODUCT; NEW DRUG; PIPERAQUINE; PRIMAQUINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRIDONE DERIVATIVE; PYRONARIDINE; QUININE; RBX 11160; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; DRUG RESEARCH; ENDEMIC DISEASE; FINANCE; HEALTH CARE DELIVERY; HEALTH PROMOTION; HUMAN; MALARIA; NEUROTOXICITY; ORGANIZATION;

EID: 23844534048     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2005.06.003     Document Type: Article

References (21)

1. C.E. Barry M. Wilson R. Lee G.K. Schoolnik DNA microarrays and combinatorial chemical libraries: Tools for the drug discovery pipeline Int. J. Tuberc. Lung Dis. 4 2000 S189-S193
2. J.A. DiMasi R.W. Hansen H.G. Grabowski L. Lasagna Cost of innovation in the pharmaceutical industry J. Health Econ. 10 1991 107-142
3. D. Fidock P.J. Rosenthal S.L. Croft R. Brun S. Nwaka Antimalarial drug discovery: Efficacy models for compound screening Nat. Rev. Drug Discov. 3 2004 509-520
4. B. Greenwood Between hope and a hard place Nature 430 2004 926-927
5. E.L. Korenromp B.G. Williams E. Gouws C. Dye R.W. Snow Measurement of trends in childhood malaria mortality in Africa: An assessment of progress towards targets based on verbal autopsy Lancet Infect. Dis. 3 2003 349-358
6. S. Nwaka R. Ridley Virtual drug discovery and development for neglected diseases through public-private partnerships Nat. Rev. Drug Discov. 2 2003 919-928
7. S. Nwaka R. Widdus The research-to-development transition for candidate products to combat 'neglected diseases' In: R. Widdus K. White (Eds.), Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential role of Public-Private Partnerships 2004 Initiative on Public-Private Partnerships for Health Geneva 164-168
8. S. Nwaka L. Riopel D. Ubben J.C. Craft Medicines for Malaria Venture - new developments in antimalarials Travel Med. Infect. Dis. 2 2004 161-170
9. R.G. Ridley Medical need, scientific opportunity and the drive for antimalarials Nature 415 2002 686-693
10. R.G. Ridley Y. Toure Winning the drugs war Nature 430 2004 942-943
11. R.W. Snow The invisible victims Nature 430 2004 934-935
12. R.W. Snow C.A. Guerra A.M. Noor H.Y. Myint S.I. Hay The global distribution of clinical episodes of Plasmodium falciparum malaria Nature 434 2005 214-217
13. R.W. Snow J.F. Trape K. Marsh The past, present and future of childhood malaria mortality in Africa Trends Parasitol. 17 2001 593-597
14. S. Sundar T.K. Jha C.P. Thakur J. Engel H. Sindermann C. Fischer K. Junge A. Bryceson J. Berman Oral miltefosine for Indian visceral leishmaniasis N. Eng. J. Med. 347 2002 1739-1746
15. T.H. Tran C. Dolecek P.M. Pham T.D. Nguyen T.T. Nguyen H.T. Le T.H. Dong T.T. Tran K. Stepniewska N.J. White J. Farrar Dihydroartemisinin-piperaquine against multi-drug resistant Plasmodium falciparum malaria in Vietnam: Randomised clinical trial Lancet 363 2004 18-22
16. P. Trouiller E. Torreek P. Olliario N. White S. Foster D. Wirth B. Pecoul Drugs for neglected diseases: A failure of the market and public health failure Trop. Med. Int. Health 6 2001 945-951
17. J.L. Vennerstrom S. Arbe-Barnes R. Brun S.A. Charman F.C. Chiu J. Chollet Y. Dong A. Dorn D. Hunziker H. Matile K. McIntosh M. Padmanilayam J. Santo Tomas C. Scheurer B. Scorneaux Y. Tang H. Urwyler S. Wittlin W.N. Charman Identification of an antimalarial synthetic trioxolane drug development candidate Nature 430 2004 900-904
18. WHO, 2001. Antimalarial Drug Combination Therapy. World Health Organization/Roll Back Malaria, Geneva, WHO/CDS/RBM/2001.35.
19. WHO, 2003a. Africa Malaria Report. World Health Organization, Geneva, WHO/CDS/MAL/2003.1093.
20. WHO, 2003b. Improving Access to Antimalarial Medicines. World Health Organization/Roll Back Malaria, Geneva, WHO/CDS/RBM/2003.44.
21. WHO, 2004. World Health Report: Changing History. World Health Organization, Geneva.